The association between persistent cognitive difficulties and depression and functional outcomes in people with major depressive disorder.

Cognitive function epidemiology longitudinal major depressive disorder predictive remote measurement

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
10 2023
Historique:
medline: 26 9 2023
pubmed: 25 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

Cognitive symptoms are common during and following episodes of depression. Little is known about the persistence of self-reported and performance-based cognition with depression and functional outcomes. This is a secondary analysis of a prospective naturalistic observational clinical cohort study of individuals with recurrent major depressive disorder (MDD; 508 individuals (81.5%) provided data (mean age: 46.6, s.d.: 15.6; 76.2% female). Increasing persistence of self-reported cognitive difficulty was associated with higher levels of depression and functional impairment throughout the follow-up. In comparison to low persistence of objective cognitive difficulty (<25% of timepoints), those with high persistence (>75% of timepoints) reported significantly higher levels of depression ( We replicated previous findings of greater persistence of cognitive difficulty with increasing severity of depression and further demonstrate that these cognitive difficulties are associated with pervasive functional disability. Difficulties with cognition may be an indicator and target for further treatment input.

Sections du résumé

BACKGROUND
Cognitive symptoms are common during and following episodes of depression. Little is known about the persistence of self-reported and performance-based cognition with depression and functional outcomes.
METHODS
This is a secondary analysis of a prospective naturalistic observational clinical cohort study of individuals with recurrent major depressive disorder (MDD;
RESULTS
508 individuals (81.5%) provided data (mean age: 46.6, s.d.: 15.6; 76.2% female). Increasing persistence of self-reported cognitive difficulty was associated with higher levels of depression and functional impairment throughout the follow-up. In comparison to low persistence of objective cognitive difficulty (<25% of timepoints), those with high persistence (>75% of timepoints) reported significantly higher levels of depression (
CONCLUSIONS
We replicated previous findings of greater persistence of cognitive difficulty with increasing severity of depression and further demonstrate that these cognitive difficulties are associated with pervasive functional disability. Difficulties with cognition may be an indicator and target for further treatment input.

Identifiants

pubmed: 37743838
doi: 10.1017/S0033291722003671
pii: S0033291722003671
pmc: PMC10520589
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6334-6344

Références

Psychol Med. 2014 Jul;44(10):2029-40
pubmed: 24168753
BMC Psychiatry. 2019 Feb 18;19(1):72
pubmed: 30777041
Front Psychiatry. 2020 Jun 24;11:546
pubmed: 32670103
J Affect Disord. 2019 Mar 1;246:763-774
pubmed: 30623822
CNS Neurol Disord Drug Targets. 2014;13(10):1787-803
pubmed: 25470389
Pituitary. 2021 Aug;24(4):542-554
pubmed: 33606176
Int J Methods Psychiatr Res. 2018 Sep;27(3):e1736
pubmed: 30088298
PLoS One. 2014 Feb 28;9(2):e90311
pubmed: 24587318
Int J Methods Psychiatr Res. 2022 Dec;31(4):e1922
pubmed: 35748111
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
J Clin Epidemiol. 2013 Sep;66(9):1022-8
pubmed: 23790725
Psychol Med. 2011 Jun;41(6):1165-74
pubmed: 20932356
Eur Neuropsychopharmacol. 2014 Jan;24(1):133-41
pubmed: 24314852
J Affect Disord. 2018 Jan 1;225:559-562
pubmed: 28869910
Clin Psychol Rev. 2020 Dec;82:101934
pubmed: 33137610
Pharmacol Ther. 2019 Oct;202:53-71
pubmed: 31173838
CNS Spectr. 2019 Feb;24(1):22-29
pubmed: 30468135
Lancet Neurol. 2002 Dec;1(8):473
pubmed: 12849328
Ann Gen Psychiatry. 2015 Sep 22;14:27
pubmed: 26396586
J Clin Psychiatry. 2009 Jul;70(7):1017-23
pubmed: 19497247
J Affect Disord. 2022 Aug 1;310:106-115
pubmed: 35525507
BMC Psychiatry. 2022 Feb 21;22(1):136
pubmed: 35189842
BMC Psychiatry. 2017 Nov 21;17(1):370
pubmed: 29157207
J Clin Psychiatry. 2017 Jul;78(7):873-881
pubmed: 28858441
Front Aging Neurosci. 2014 Feb 24;6:21
pubmed: 24605100
Sci Rep. 2017 Jun 20;7(1):3901
pubmed: 28634383
J Affect Disord. 2017 Nov;222:14-20
pubmed: 28667888
Psychiatry Res. 2014 Sep 30;219(1):25-50
pubmed: 24863864
BMC Med Res Methodol. 2011 Sep 21;11:131
pubmed: 21936925
Psychiatry Res. 2010 Aug 30;179(1):101-6
pubmed: 20472297
Clin Psychol Rev. 2021 Jun;86:102007
pubmed: 33864968
Psychol Med. 2013 Oct;43(10):2017-26
pubmed: 23098294
Psychiatry Res. 2012 Aug-Sep;203(2-3):222-8
pubmed: 22964135
Behav Cogn Psychother. 2021 Aug 13;:1-5
pubmed: 34384507

Auteurs

F Matcham (F)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
School of Psychology, University of Sussex, Falmer, UK.

S K Simblett (SK)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

D Leightley (D)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

M Dalby (M)

Muna Therapeutics, Copenhagen, Denmark.

S Siddi (S)

Parc Sanitari Sant Joan de Déu, Fundació San Joan de Déu, Universitat de Barcelona, CIBERSAM, Barcelona, Spain.

J M Haro (JM)

Parc Sanitari Sant Joan de Déu, Fundació San Joan de Déu, Universitat de Barcelona, CIBERSAM, Barcelona, Spain.

F Lamers (F)

Department of Psychiatry, Amsterdam UMC location Vrije Universiteit Amsterdam, Boelelaan 1117, Amsterdam, The Netherlands.
Amsterdam Public Health, Mental Health Program, Amsterdam, The Netherlands.

B W H J Penninx (BWHJ)

Department of Psychiatry, Amsterdam UMC location Vrije Universiteit Amsterdam, Boelelaan 1117, Amsterdam, The Netherlands.
Amsterdam Public Health, Mental Health Program, Amsterdam, The Netherlands.

S Bruce (S)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

R Nica (R)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
The Romanian League for Mental Health, Bucharest, Romania.

S Zormpas (S)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
EPIONI Greek Carers Network, Athens, Greece.

G Gilpin (G)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

K M White (KM)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

C Oetzmann (C)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

P Annas (P)

H. Lundbeck A/S, Copenhagen, Denmark.

J C Brasen (JC)

H. Lundbeck A/S, Copenhagen, Denmark.

V A Narayan (VA)

Janssen Pharmaceutica NV, New York, USA.

M Hotopf (M)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

T Wykes (T)

The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH